Search 

apceth is a privately held German Biotech company focused on the development and clinical implementation of innovative biopharmaceuticals based on cell and gene therapy in the field of oncology.

Enabling platform technology for genetic modification of mesenchymal stem cells (MSC) to be used as drug shuttle to target tumors or other areas of interest.

Clinical development:

phase I with modified MSC in gastro-intestinal tumors completed (12/2014)

phase I/II with MSC for vascular disease completed

strong clinical pipeline based on genetic modification of MSC

Implementation of allogeneic cell bank system to accomodate off-the-shelf production of cell-based pharmaceuticals.

Strong network and IP,

interesting preclinical pipeline addressing oncology, lung disease, inflammation.

Secure financing by German Family Offic. Looking for partner/ cofinancing for ongoing clinical development (phase II/III)

For more than 35 years STRATEC Biomedical AG is a business partner for the development and manufacture of fully automated analyzer systems. It's headquarter is located in Birkenfeld, Germany and it has nearly 500 employees in 5 locations worldwide. The public owned company has cooperations with 15 of the 20 IVD companies worldwide and has boosted its annual sales from USD 10.4 million in 1998 (IPO) to USD 122.4 million in 2014. STRATEC has strived to achieve market-leading expertise and to build a technology pool that is unique to its industry. The company invests in a variety of fields within the diagnostic and life science sector including medical devices.

Wellington Partners is a venture capital firm based in Munich, Germany, with an additional office in Zurich, Switzerland. The firm specializes in early-stage and growth capital investments in the Technology and Life Sciences sector. The firm has approximately €800M AUM and is currently investing out of a €100M fund for Life Science companies. Depending on the stage of the company, the firm can allocate up to €10M over the life of the investment. The firm can also lead or co-lead financing rounds of up to €30M or higher with syndicates. The firm focuses on European companies but will consider US-based companies with activities in Europe. The firm is actively seeking new investment opportunities.